Abcellera Biologics Inc ABCL

$11.37 -0.87 (-7.11%)

Valuation

Market cap
3,752,919,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
4,272,100
Avg volume
5,689,402
Day's range
$11.20 – $12.23
Shares out
306,611,000
Stochastic %K
9%
Beta
1.41
Analysts
Strong Sell
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Stocktradesmoon Oct 23, 8:21 AM
$ABCL Three signals I look for in a platform biotech: large partners signing, internal assets reaching the clinic, and a balance sheet that never forces a bad deal. $ABCL showed all three this summer. That combination is rare in small cap biotech.
0 replies
Stocktradesmoon Oct 23, 8:15 AM
$ABCL UPDATE: 🚨 ABCL Q3 EARNINGS AND CLINICAL CATALYSTS $ABCL has announced its participation schedule for the November investor conference. I see this announcement as more than just a notice for an institutional investor event—it's connected to the next clinical phase of ABCL635. In particular, we need to watch whether the 12-week data we've all been waiting for will be unveiled during the November 9 earnings release, or if it will lead to a separate announcement afterward. 1. Upcoming Key Schedule October 22 Poster presentation on ABCL635 Phase 1/2 clinical trial at the TMS 2026 Conference November 9 Q3 2026 Earnings Release and Conference Call 7:00 AM Korea Time on November 10 November 11 Stifel Healthcare Conference November 16 Jefferies Global Healthcare Conference Q4 2026 ABCL575 Phase 1 clinical results presentation scheduled By end of 2026 Expect 12-week data for ABCL635 and updates on subsequent clinical information
0 replies
Ckkung71 Oct 23, 8:14 AM
$ABCL The news: Over the past ~3 weeks—from late September to mid-October—AbCellera has seen a wave of senior-level hiring. The key lies in the specific roles: Head of Quality Assurance, Director/Senior Director of QC, Director of QA Validation, Head of Process Development (CMC), and Head of CMC Portfolio Management. Layer by layer: A core QC team (June) → operations and translational science (July) → VP of Medical Affairs (September) → and now, senior leadership in Quality and CMC (October). Each step represents a move further up the value chain than the last. My take: A company doesn’t build out a full senior leadership layer for quality and manufacturing unless it anticipates having a product to manufacture and sell. Following the positive Phase 2 results this summer, the focus has shifted from mere hope to actual realization. The direction is clear—onward.
1 replies
Stocktradesmoon Oct 23, 8:08 AM
$ABCL 👏👏👏👀 $ABCL One injection followed by 4 weeks later, 37.0% of patients had flushing completely disappear. Placebo: 2.2% 💉 - Patients with 90% or more reduction: 60.9% vs placebo 8.7% (Phase 2, 92 people, 600mg single dose) - Difference from placebo widened from 2.6 episodes/day (week 1) to 5.5 episodes/day (week 4) - 84% of patients responded "much/quite improved" (placebo 27%) - 12 healthy postmenopausal women received 3 injections at 4-week intervals, and average liver values up to Phase 2 were similar to placebo. No gastrointestinal or liver abnormality signals - Half-life about 24 days, under development as monthly injection. Headache more frequent at 28.2% vs 13.0%, but mostly mild
0 replies
tranq19 Oct 23, 8:02 AM
$ABCL so really nothing new, waiting on 12 week data. Only new bit was repeat dose safety confirmation
0 replies
Stocktradesmoon Oct 23, 4:43 AM
$ABCL “BLOWN-AWAY” by the 2026 TMS Conference TODAY 🔥!!! Just WOW! 😮 🤯 Great job 👏 to the Menopause Society!! Honestly, it was remarkable. The scale of the event, the energy in the room, and the quality of the presentations were on another level. I was blown away by the whole experience. Everything felt so thoughtfully curated, and there were so many impressive people in attendance. It was one of those events that genuinely leaves an impression on you. The atmosphere, the insights, the networking—it was all exceptional. The entire convention was incredibly impressive.It was clear that a tremendous amount of effort went into making it such a high-caliber event. Thank you!
0 replies
Bastox Oct 23, 12:56 AM
$ABCL Is PR/IR gonna put anything out? C’mom
0 replies
Samb2344 Oct 23, 12:27 AM
$ABCL
1 replies